ID   C1R-A24
AC   CVCL_S990
SY   C1RA24
DR   Cosmic; 1995351
DR   Wikidata; Q54807880
RX   PubMed=17982631;
RX   PubMed=19123955;
CC   Population: Caucasian.
CC   Transfected with: HGNC; 4931; HLA-A (allele A*24:02).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3714 ! HMy2.C1R
SX   Female
AG   33Y
CA   Transformed cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 12
//
RX   PubMed=17982631; DOI=10.3892/or.18.6.1463;
RA   Komohara Y., Harada M., Ishihara Y., Suekane S., Noguchi M.,
RA   Yamada A., Matsuoka K., Itoh K.;
RT   "HLA-G as a target molecule in specific immunotherapy against renal
RT   cell carcinoma.";
RL   Oncol. Rep. 18:1463-1468(2007).
//
RX   PubMed=19123955; DOI=10.1186/1479-5876-7-1;
RA   Kobayashi J.-i., Torigoe T., Hirohashi Y., Idenoue S., Miyazaki A.,
RA   Yamaguchi A., Hiratsuka H., Sato N.;
RT   "Comparative study on the immunogenicity between an HLA-A24-restricted
RT   cytotoxic T-cell epitope derived from survivin and that from its
RT   splice variant survivin-2B in oral cancer patients.";
RL   J. Transl. Med. 7:1.1-1.11(2009).
//